C4 Therapeutics Inc

NASDAQ:CCCC   3:59:53 PM EDT
11.58
-0.67 (-5.47%)
Earnings Announcements

C4 Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 13:49 GMT
C4 Therapeutics Inc (CCCC) - C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights.
Q2 Loss per Share $0.56.
Q2 Revenue $13.8 Million.
C4 Therapeutics - Expects Cash, Equivalents As of June 30, to Be Sufficient to Fund Planned Operating Expenses and Capital Expenditures to 2024-end.
Revenue is expected to be $8.36 Million
Adjusted EPS is expected to be -$0.71

Next Quarter Revenue Guidance is expected to be $7.79 Million
Next Quarter EPS Guidance is expected to be -$0.79

More details on our Analysts Page.